<?xml version='1.0' encoding='utf-8'?>
<document id="27310328"><sentence text="Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir."><entity charOffset="25-35" id="DDI-PubMed.27310328.s1.e0" text="Omeprazole" /><entity charOffset="80-92" id="DDI-PubMed.27310328.s1.e1" text="Paritaprevir" /><entity charOffset="93-102" id="DDI-PubMed.27310328.s1.e2" text="Ritonavir" /><entity charOffset="107-117" id="DDI-PubMed.27310328.s1.e3" text="Ombitasvir" /><entity charOffset="135-144" id="DDI-PubMed.27310328.s1.e4" text="Dasabuvir" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e0" e2="DDI-PubMed.27310328.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e0" e2="DDI-PubMed.27310328.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e0" e2="DDI-PubMed.27310328.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e0" e2="DDI-PubMed.27310328.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e0" e2="DDI-PubMed.27310328.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e1" e2="DDI-PubMed.27310328.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e1" e2="DDI-PubMed.27310328.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e1" e2="DDI-PubMed.27310328.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e1" e2="DDI-PubMed.27310328.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e2" e2="DDI-PubMed.27310328.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e2" e2="DDI-PubMed.27310328.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e2" e2="DDI-PubMed.27310328.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e3" e2="DDI-PubMed.27310328.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s1.e3" e2="DDI-PubMed.27310328.s1.e4" /></sentence><sentence text="Paritaprevir (administered with low-dose ritonavir), ombitasvir, and dasabuvir are direct-acting antiviral agents administered as combination regimens for the treatment of chronic hepatitis C virus infection"><entity charOffset="0-12" id="DDI-PubMed.27310328.s2.e0" text="Paritaprevir" /><entity charOffset="41-50" id="DDI-PubMed.27310328.s2.e1" text="ritonavir" /><entity charOffset="53-63" id="DDI-PubMed.27310328.s2.e2" text="ombitasvir" /><entity charOffset="69-78" id="DDI-PubMed.27310328.s2.e3" text="dasabuvir" /><pair ddi="false" e1="DDI-PubMed.27310328.s2.e0" e2="DDI-PubMed.27310328.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27310328.s2.e0" e2="DDI-PubMed.27310328.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27310328.s2.e0" e2="DDI-PubMed.27310328.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s2.e0" e2="DDI-PubMed.27310328.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s2.e1" e2="DDI-PubMed.27310328.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27310328.s2.e1" e2="DDI-PubMed.27310328.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s2.e1" e2="DDI-PubMed.27310328.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s2.e2" e2="DDI-PubMed.27310328.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s2.e2" e2="DDI-PubMed.27310328.s2.e3" /></sentence><sentence text=" Drug-drug interactions between 2D (ombitasvir/paritaprevir/ritonavir) or 3D (ombitasvir/paritaprevir/ritonavir and dasabuvir) regimens and omeprazole, a CYP2C19 substrate and acid-reducing agent, were evaluated in 24 healthy volunteers"><entity charOffset="36-46" id="DDI-PubMed.27310328.s3.e0" text="ombitasvir" /><entity charOffset="47-59" id="DDI-PubMed.27310328.s3.e1" text="paritaprevir" /><entity charOffset="60-69" id="DDI-PubMed.27310328.s3.e2" text="ritonavir" /><entity charOffset="78-88" id="DDI-PubMed.27310328.s3.e3" text="ombitasvir" /><entity charOffset="89-101" id="DDI-PubMed.27310328.s3.e4" text="paritaprevir" /><entity charOffset="102-111" id="DDI-PubMed.27310328.s3.e5" text="ritonavir" /><entity charOffset="116-125" id="DDI-PubMed.27310328.s3.e6" text="dasabuvir" /><entity charOffset="140-150" id="DDI-PubMed.27310328.s3.e7" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e0" e2="DDI-PubMed.27310328.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e0" e2="DDI-PubMed.27310328.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e0" e2="DDI-PubMed.27310328.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e0" e2="DDI-PubMed.27310328.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e0" e2="DDI-PubMed.27310328.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e0" e2="DDI-PubMed.27310328.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e0" e2="DDI-PubMed.27310328.s3.e6" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e0" e2="DDI-PubMed.27310328.s3.e7" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e1" e2="DDI-PubMed.27310328.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e1" e2="DDI-PubMed.27310328.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e1" e2="DDI-PubMed.27310328.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e1" e2="DDI-PubMed.27310328.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e1" e2="DDI-PubMed.27310328.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e1" e2="DDI-PubMed.27310328.s3.e6" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e1" e2="DDI-PubMed.27310328.s3.e7" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e2" e2="DDI-PubMed.27310328.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e2" e2="DDI-PubMed.27310328.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e2" e2="DDI-PubMed.27310328.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e2" e2="DDI-PubMed.27310328.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e2" e2="DDI-PubMed.27310328.s3.e6" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e2" e2="DDI-PubMed.27310328.s3.e7" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e3" e2="DDI-PubMed.27310328.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e3" e2="DDI-PubMed.27310328.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e3" e2="DDI-PubMed.27310328.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e3" e2="DDI-PubMed.27310328.s3.e6" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e3" e2="DDI-PubMed.27310328.s3.e7" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e4" e2="DDI-PubMed.27310328.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e4" e2="DDI-PubMed.27310328.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e4" e2="DDI-PubMed.27310328.s3.e6" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e4" e2="DDI-PubMed.27310328.s3.e7" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e5" e2="DDI-PubMed.27310328.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e5" e2="DDI-PubMed.27310328.s3.e6" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e5" e2="DDI-PubMed.27310328.s3.e7" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e6" e2="DDI-PubMed.27310328.s3.e6" /><pair ddi="false" e1="DDI-PubMed.27310328.s3.e6" e2="DDI-PubMed.27310328.s3.e7" /></sentence><sentence text=" Subjects received omeprazole (40 mg once daily) on day 1 and days 20-24 and the 2D or 3D regimen (ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily Â± dasabuvir 250 mg twice daily) on days 6-24"><entity charOffset="19-29" id="DDI-PubMed.27310328.s4.e0" text="omeprazole" /><entity charOffset="99-109" id="DDI-PubMed.27310328.s4.e1" text="ombitasvir" /><entity charOffset="110-122" id="DDI-PubMed.27310328.s4.e2" text="paritaprevir" /><entity charOffset="123-132" id="DDI-PubMed.27310328.s4.e3" text="ritonavir" /><entity charOffset="160-169" id="DDI-PubMed.27310328.s4.e4" text="dasabuvir" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e0" e2="DDI-PubMed.27310328.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e0" e2="DDI-PubMed.27310328.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e0" e2="DDI-PubMed.27310328.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e0" e2="DDI-PubMed.27310328.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e0" e2="DDI-PubMed.27310328.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e1" e2="DDI-PubMed.27310328.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e1" e2="DDI-PubMed.27310328.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e1" e2="DDI-PubMed.27310328.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e1" e2="DDI-PubMed.27310328.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e2" e2="DDI-PubMed.27310328.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e2" e2="DDI-PubMed.27310328.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e2" e2="DDI-PubMed.27310328.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e3" e2="DDI-PubMed.27310328.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s4.e3" e2="DDI-PubMed.27310328.s4.e4" /></sentence><sentence text=" Compared with omeprazole alone, coadministration with the 2D or 3D regimen decreased omeprazole geometric mean Cmax and AUCt values by 40% to 50%"><entity charOffset="15-25" id="DDI-PubMed.27310328.s5.e0" text="omeprazole" /><entity charOffset="86-96" id="DDI-PubMed.27310328.s5.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.27310328.s5.e0" e2="DDI-PubMed.27310328.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27310328.s5.e0" e2="DDI-PubMed.27310328.s5.e1" /></sentence><sentence text=" Ombitasvir, dasabuvir, and ritonavir mean exposures showed &lt;10% change, and paritaprevir mean exposures showed &lt;20% change when the 2D or 3D regimen was administered with omeprazole compared with administration without omeprazole"><entity charOffset="1-11" id="DDI-PubMed.27310328.s6.e0" text="Ombitasvir" /><entity charOffset="13-22" id="DDI-PubMed.27310328.s6.e1" text="dasabuvir" /><entity charOffset="28-37" id="DDI-PubMed.27310328.s6.e2" text="ritonavir" /><entity charOffset="77-89" id="DDI-PubMed.27310328.s6.e3" text="paritaprevir" /><entity charOffset="172-182" id="DDI-PubMed.27310328.s6.e4" text="omeprazole" /><entity charOffset="220-230" id="DDI-PubMed.27310328.s6.e5" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e0" e2="DDI-PubMed.27310328.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e0" e2="DDI-PubMed.27310328.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e0" e2="DDI-PubMed.27310328.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e0" e2="DDI-PubMed.27310328.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e0" e2="DDI-PubMed.27310328.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e0" e2="DDI-PubMed.27310328.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e1" e2="DDI-PubMed.27310328.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e1" e2="DDI-PubMed.27310328.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e1" e2="DDI-PubMed.27310328.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e1" e2="DDI-PubMed.27310328.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e1" e2="DDI-PubMed.27310328.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e2" e2="DDI-PubMed.27310328.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e2" e2="DDI-PubMed.27310328.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e2" e2="DDI-PubMed.27310328.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e2" e2="DDI-PubMed.27310328.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e3" e2="DDI-PubMed.27310328.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e3" e2="DDI-PubMed.27310328.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e3" e2="DDI-PubMed.27310328.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e4" e2="DDI-PubMed.27310328.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27310328.s6.e4" e2="DDI-PubMed.27310328.s6.e5" /></sentence><sentence text=" Although no a priori dose adjustment is needed, a higher omeprazole dose should be considered if clinically indicated when coadministered with the 2D or 3D regimen"><entity charOffset="58-68" id="DDI-PubMed.27310328.s7.e0" text="omeprazole" /></sentence><sentence text=" No dose adjustment is required for the 2D or 3D regimen when administered with omeprazole, other acid-reducing agents, or CYP2C19 inhibitors"><entity charOffset="80-90" id="DDI-PubMed.27310328.s8.e0" text="omeprazole" /></sentence><sentence text=" " /></document>